of folic acid or folic acid + fortified foods and/or natural food folates for a minimum of 4 weeks, there were no significant differences in plasma homocysteine levels; however, individuals with the TT genotype had a lower serum folate response to supplementation (7.2 nmol/L, TT vs. CT/ CC; 8.7 nmol/L, TT vs. CC). Conclusions This meta-analysis confirms observations from observational and intervention studies that MTHFR TT genotype is associated with increased plasma homocysteine and lowered serum folate and less response to short-term supplementation. The results can be used for modelling and guiding personalised intake recommendations for the nutrient folate.
Introduction
Adequate folate status is associated with a reduced risk of neural tube defects [1] and may protect against certain cancers [2] cognitive dysfunction [3] [4] [5] , and coronary heart disease [6] . Folate status is an important determinant of homocysteine (Hcy) levels [7] which, when elevated, increase the risk of cardiovascular disease [8] . Supplementation with folic acid, the synthetic folate vitamer, has been shown to reduce homocysteine levels [9, 10] and improve vascular function [11, 12] .
While there is considerable evidence to indicate that adequate folate status is associated with reduction in risk of certain diseases, there is some suggestion that a high intake of folic acid may increase disease risk. For example, there is current debate about whether folic acid fortification can cause or increase cancer risk [13] , although this is yet to be proven. High intake of folic acid is known to mask B 12
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The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) plays a key role in folate metabolism converting 5, 10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the main form of circulatory folate and the methyl donor for the conversion of homocysteine to methionine [21] . The C677T mutation in the MTHFR gene, which results in an alanine to valine (A222V) substitution in exon 4, causes reduced enzyme activity and increased thermolability, particularly in folate deficient states [22] . Individuals homozygous for the mutation have significantly elevated plasma Hcy levels and lower plasma folate levels [23, 24] . Not surprisingly, the MTHFR 677T variant has been implicated in an increased risk of neural tube defects [25] .
Due to the relationship between neural tube defects and inadequate folate status, many countries have adopted mandatory folic acid fortification of cereal grain products. [26] . Studies in these countries have reported increased serum folate and reduced Hcy levels [27, 28] and reduced rates of neural tube defects [29, 30] at the population level. Nevertheless, certain subgroups of the population, particularly young women of child-bearing age, continue to have suboptimal intake of folates from food and/or supplements [31, 32] . There is uncertainty about sufficient intake for individuals with the MTHFR 677TT genotype, who likely have increased requirements compared to those with the CC and CT genotypes [24] , particularly with low folate status [33] . A study in Mexican-American men suggested that 400 μg per day as dietary folate equivalents (DFEs), a standardised method to adjust for bioequivalence between natural and synthetic folates where 1 μg DFE = 1 μg food folate or 0.6 μg folic acid with food [34] , was not sufficient for TT individuals [35] . Thus, there is a need to establish an adequate minimum intake that incorporates the requirements of genetic variability. It should override any modulatory effect of the deficiency in the MTHFR enzyme and normalise folate status as well as minimise potential side effects of chronic high doses of folic acid. Intake recommendations for folates vary around the world with several countries recommending an additional intake of 400 μg DFE per day for women who are capable of becoming pregnant or whose diet is inadequate [36] .
Thus, the aim of our study was firstly to determine the level at which the MTHFR C677T genotype influenced folate status as evidenced by pre-supplementation measurement of homocysteine and plasma folate levels, and further to determine the impact of supplementation of folic acid or folic acid + fortified foods and natural food folates according to MTHFR C677T genotype. Although a number of individual studies have been undertaken to examine this, a single study may lack the power to fully examine the complex nutrigenetic relationship due to small sample size. A meta-analysis may override these limitations. To our knowledge, this is the first meta-analysis of folate intervention studies that has been undertaken to examine the response on folate status according to genotype in both males and females.
Methodology
A systematic literature search of published studies was undertaken. The databases PubMed, Scopus, Cochrane Library, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched for studies published in English up to Jun 2015, using the following Standard Medical Subject Headings (MeSH), without imposing any time limitation: MTHFR, methylenetetrahydrofolate reductase, 5, 10-methylenetetrahydrofolate reductase, and folate or folic acid. References from all relevant literature were hand-searched and used to identify any additional relevant studies. The results of the search strategy are summarised in Fig. 1 . There were 2542 articles initially identified. From those, 2161 were not relevant, leaving 381 articles that required closer inspection by examining the abstract and full text if necessary. From this inspection, there were 26 potential studies for the meta-analysis. Of the 26 studies, 16 were unsuitable because of lack of genotyping data or folate measurements, unsuitability of methodology, potential interaction of other medications/supplements with folate status, supplementation greater than 1 mg folic acid per day, and data that came from another included study. Ten studies were considered potentially suitable for the meta-analysis. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis: The PRISMA Statement were followed as a guideline for conducting this systematic review and meta-analysis [37] .
To be eligible for the data to be included in the metaanalysis, studies needed to be human intervention supplementation studies of folic acid or folic acid plus a folic acid fortified diet and/or natural food folates (but not natural food folates alone due to variability in bioavailability due to processing/storage, etc. [38] ). Studies needed to include pre-and post-supplementation and end measures of plasma or serum Hcy and/or folate categorised by MTHFR C677T genotype group. To minimise differences between countries with fortification and those without, studies were excluded if depletion diets were not undertaken for a minimum of 6 weeks prior to intervention in countries in which there was mandatory folic acid fortification. This should better represent folate status from typical diets that are not fortified under mandatory fortification conditions. Studies could be either a randomised controlled trial (parallel or crossover) or a quasi-experimental trial, with or without placebo, of at least a 4-week period. The minimum dose for inclusion was 400 μg DFEs as folic acid or folic acid + fortified food and/or natural food folates daily as this dose is a commonly adopted nutrient intake value, and frequently recommended supplement amount for women capable of becoming pregnant [36] . In addition, a meta-analysis by The Homocysteine Lowering Trialist's Collaboration determined that 400 μg of folic acid was associated with 90 % of the maximal reduction in blood homocysteine concentrations produced by folic acid [39] . Notably, some supplementation studies report an average increase in serum and red cell folate, and a reduction in Hcy at smaller daily doses of folate such as 200 μg per day and for short periods such as 4 weeks [40] [41] [42] [43] , but not all studies report that smaller daily doses of folic acid lower Hcy significantly [44] . The maximum dose for inclusion was 1 mg of folic acid per day as this is considered the upper tolerable limit [45, 46] . Participants needed to be at least 18 years old without chronic illness that would affect folate status, and not pregnant. Participants could not be taking any supplements or medications that would affect folate status just prior to and during the study. Publications needed to be in English. There was no restriction on ethnicity due to the common effect of the MTHFR variant [47] .
Two researchers conducted the initial literature screening independently. The decision regarding inclusion or exclusion of articles was made through agreement between the two researchers. A third researcher was involved in the decision-making in case of any disagreement. This occurred with one study, which was eventually excluded from the final meta-analysis. The next phase involved a review of abstracts and an examination of the full text in terms of the eligibility criteria. The screening process involved review of the title, abstract, and full text of the literature. A summary of the review is presented in the study flow diagram (Fig. 1 ). Included articles were reviewed to assess their publication bias and to extract relevant data.
Data extraction
The "checklist of items to consider in data collection" from the Cochrane Handbook for Systematic Review of Interventions was followed to extract relevant data [48] . Characteristics of the included studies are presented in Table 1 . The following information was extracted from each study that was considered eligible: the first author's name, the year of publication, the sample size, gender and ethnicity of participants, the study design, the genotyping method, the genotype frequency, the supplementation dose, the length of the intervention, mean and standard deviation (SD) for pre-and post-supplementation measures of plasma or serum Hcy, and folate in the genotype categories. Where SDs were not available, they were imputed according to the method described by Furukawa et al. [49] . All plasma Hcy measures were in μmoles per litre (μmol/L). All serum folate measures were reported in standard international (SI) units of nanomoles per litre (nmol/L). Any that were reported in nanograms per millilitre (ng/mL) were converted using the formula described in the NHANES [50] : serum and red cell folate in ng/mL to SI units (nmol/L), multiply by 2.265.
Following the data eligibility and ineligibility criteria described earlier, ten studies were eventually included in the meta-analysis. Six were randomised controlled trials, and four were quasi-experimental trials (see Table 1 ). Although randomised controlled trials are generally considered the design of choice for the assessment of the effectiveness of health-related interventions, there are many instances where non-randomised studies have either been sufficient to demonstrate effectiveness or have arrived at similar results [51] . While the Cochrane methodology for meta-analyses does not recommend combining randomised and non-randomised studies, it can be argued that in order to examine the effect of supplementation on the measurable outcomes of folate status, despite obvious differences in the methodology and risk of bias in the two types of studies, it is acceptable to include both in the analysis [52] . Notably, where randomised controlled trials compared naturally occurring food folate to folic acid supplementation, measures for the folic acid supplementation group only were used. Among the ten studies, five studies recruited healthy staff and students from local universities [53] [54] [55] [56] or a university medical centre [57] . One study recruited hypertensive individuals from hospitals in China [58] , while another recruited individuals who had suffered miscarriages [59] . The remaining three studies did not disclose recruitment strategies [60] [61] [62] . All but one study [55] described details of screening and exclusion criteria, such as pregnancy, chronic disease, anaemia, B 12 deficiency, and alcohol misuse.
Laboratory methods
All studies took fasting blood samples to determine Hcy and folate status. To determine plasma total Hcy, all studies used a version of the high-performance liquid chromatography (HPLC) fluorometric method. For those with serum folate data (eight studies), to determine measurements, one study used a radioactive assay technique [59] , one used a competitive protein-binding method [56] , three used chemiluminescent immunoassay [55, 58, 60] , and three used microbial assays [53, 57, 62] . Due to the reported variation in blood folate measurements between different assay methods [63] , a student's t test of measures performed by chemiluminescent immunoassay compared to microbial assay was undertaken for the whole group and then all genotype groups pre-and post-supplementation. There were no significant differences in any of the comparisons (whole group p = 0.2; pre-supplementation CC p = 0.9, CT p = 0.3, TT p = 0.4; post-supplementation CC p = 0.3, CT p = 0.6, TT p = 0.3) For MTHFR genotyping, all but two studies used PCR and restriction fragment length polymorphism genotyping using Hinf1, originally described by Frosst et al. [64] . Ashfield-Watt used heteroduplex analysis, and Crider used allele-specific hybridisation [56, 57] .
Statistical analysis
Data were analysed using the Cochrane Collaboration's software, Review Manager (Revman) 5.3 [52] . Measures of serum homocysteine and serum or plasma folate were analysed as continuous variables. As we were particularly interested in the effect in the homozygous carriers of the T allele, we applied two genetic models comparing TT carriers against either all other carriers (CT + CC) or CC homozygotes. We named these two models as Recessive Model (TT vs. CT and CC) and Homozygous Model (TT vs. CC), and the names will be used in the rest of this paper. Weighted averages were calculated to produce the comparison groups if not reported directly.
As the units of measurement were the same across the trials, the overall comparison was reported by the mean difference [65] . To account for the heterogeneity of the studies for the comparisons, the DerSimonian-Laird random-effects model was applied to the analysis. This random-effects model assigns a weight to each study, inversely proportional to the within-study sampling variance. The weights reflect the relative "value" of the information provided in a study and allow for diversity between the different studies in the meta-analysis [66, 67] .
To examine if the results of the meta-analysis could have depended on a few studies with special characteristics, sensitivity and subgroup analyses were undertaken. The total effect of each study on the overall results of the meta-analysis was examined, as well as adding and removing femaleonly studies [53, 55, 57, 61, 62] , the largest and smallest doses [54, 60] , those that chose for mild hyperhomocysteinemia [54, 68] , those in countries with folic acid food fortification [53, 62] , those that supplemented for more than 8 weeks [54, 56, 57, 59, 60] , and quasi-experimental trials [53, 55, 59, 62] so that only randomised controlled trials were analysed together according to the method described by Kavvoura and Ioannidis [69] . Studies in Chinese populations [57, 58] were also analysed in a subgroup due to genetic similarity [70] .
Results

Quality analysis
A methodological quality analysis was developed based on a modified version of Downs and Black's checklist [71] , and the American Dietetic Association Research Design and Implementation checklist for primary research [72] . Downs and Black's checklist was modified to include a question on comparison of baseline characteristics as advised by Deeks et al. [51] in their report on evaluating non-randomised intervention studies. This resulted in a thirty-question scored checklist examining potential flaws in the design of each study that could bias the overall results of the meta-analysis. The checklist examined several aspects of reporting (description of the research question, protocol, intervention, findings) external validity (whether the treatment group was representative), internal validity (whether there was bias in randomisation, blinding of participants and investigators, compliance, potential for reporting bias), and statistical and genetic analysis methodology. In addition, if genotype selection was not involved, studies were assessed for Hardy-Weinberg Equilibrium (HWE) using the goodness-of-fit Chi-square test (Supplemental Table 1 ). The methodology quality of included articles was also assessed using the Rosendal scale [73] . An overall Rosendal score of 60 % was regarded as an excellent methodology quality [74] . A total of twelve studies (1875 participants) were included in qualitative synthesis and quantitative synthesis (Supplemental Table 2 ). Zappacosta et al. [54] had the lowest Rosendal score of 53 %, and the highest Rosendal score of 86 % belonged to Miyaki et al. [60] study.
Pre-supplementation plasma homocysteine
Nine studies examined Hcy levels according to MTHFR C677T genotype. The subgroup and sensitivity analyses in Table 2 showed that restricting studies to randomised controlled trials had a slightly stronger effect at 3.4 μmol/L [1.9-4.8] for the recessive model and 4.0 μmol/L [2.0-5.9] for the homozygous model. Results were still significant when the study with the largest dose of 1 mg/folic acid per day (Miyaki et al. [60] ) was removed and the study with the most extreme value was removed (Qin et al. [58] ). The mean difference was notably higher in the Chinese subgroup which included two studies, Crider et al. [57] and Qin et al. [58] . The difference was 6.9 μmol/L [0.2-13.5] for the dominant model and 7.4 μmol/L [0.5-13.5] for the homozygous model.
Post-supplementation plasma homocysteine
Seven studies examined the effect of supplementation on plasma Hcy levels according to MTHFR C677T genotype. Figure 3 illustrates results of pooled analysis using recessive and homozygous models. All groups in all studies had reduced mean plasma Hcy. Both models showed no significant difference in mean plasma Hcy between the TT genotype group (n = 200) and the CC/CT genotype group (n = 486) for the recessive model (p = 0.6) or the TT genotype group (n = 171) compared with the CC genotype group (n = 155) in the homozygous model (p = 0.46) after supplementation. No studies in the either genotype group had mean Hcy levels >15 μmol/L. The subgroup and sensitivity analyses in Table 3 show no significant results in any of the subgroup analyses.
Pre-supplementation serum folate
Nine studies examined serum folate levels according to MTHFR C677T genotype. Figure 4 shows results of pooled analysis using recessive and homozygous genetic models. The TT group (n = 298) had a statistically significant lower mean of 2.5 nmol/L [95 % CI 1.2-3.7] for serum folate, compared to those in the CC/CT group (n = 925) for the recessive model, and for the homozygous model, the TT group (n = 315) had a statistically significant lower mean of 3.6 nmol/L [95 % CI 2.1-5.0] compared to those in the CC group (n = 371). The means for all groups were >7 nmol/L. The lowest means were 7.3 nmol/L and 9.1 nmol/L in the TT group of two studies. Subgroup and sensitivity analyses (Table 4) show that the effect was similar for all subgroups. The Chinese population analysis was difficult to interpret because of heavy weighting of the Crider study at 75 % and 99 % for both the recessive and homozygous models. Eight studies examined serum folate levels after supplementation according to MTHFR C677T genotype. Figure 5 illustrates results of pooled analyses. All groups in all studies showed an increase in mean serum folate levels with the lowest means being 14 nmol/L and 19 nmol/L for the TT and CC or CT/CC groups for the same study [53] . Pooled analysis showed that in both genetic models the TT genotype group (n = 271) had lower mean serum folate levels of 7.2 nmol/L [95 % CI 5.0-9.3] when compared to the CT/CC genotype group (n = 774) in the recessive model and 8.7 nmol/L [95 % CI 6.3-11.0] when compared to the CC genotype group (n = 301) in the homozygous model. Subgroup and sensitivity analyses (Table 5) show that the effect remained strong for all subgroups. We also analysed studies that supplemented for >8 weeks together to examine of length of supplementation had an effect. Differences between the groups were 8.4 nmol/L [95 % CI 6.0-10.7] for the recessive model and 11.2 nmol/L [95 % CI 8.3-14.1] for the homozygous model, suggesting that differences increased when supplementation was for a longer time. This was a surprising result; however, we acknowledge that the maximum duration in the studies examined was 24 weeks, which may not reflect response to longterm supplementation studies or from populations under fortification.
Discussion
The aim of this meta-analysis was to take a nutrigenetic approach to examine how the MTHFR 677 genotype, which has been associated with reduced folate status [23, 24] , influences blood homocysteine and folate levels pre-and post-supplementation with folic acid or folic acid + food folates (natural or fortified). Overall, the results showed that prior to supplementation, groups with the TT genotype had statistically significant higher plasma Hcy levels compared to the CC and CT genotype (recessive model) at 2.7 μmol/L and at 2.8 μmol/L when compared to the CC genotypes (homozygote model). In two of the studies analysed, the TT groups had Hcy levels >15 μmol/L. This was not seen in the other genotype groups. The subgroup analysis showed an even stronger effect in the two studies undertaken in Chinese populations at differences of 6.9 μmol/L (TT vs. CT/CC) and 7.4 μmol/L (TT vs. CC), although neither study had mean Hcy levels >15 μmol/L in any of the genotype groups.
Interestingly, a high prevalence of hyper-Hcy in Chinese populations has been previously described [75] . In fact, a 2015 meta-analysis of 60,754 subjects reported a prevalence of 27.5 %, with low dietary folate proposed as an important determinant [76] . As the MTHFR T variant interacts with dietary folate, this may partly explain our findings in this subgroup. The pooled analysis of serum folate levels showed that the TT groups had significantly lower levels compared to the CC and CT groups at 2.45 nmol/L (TT vs. CT/CC) and 3.6 nmol/L (TT vs CC), although none of the groups had serum folate levels <7 nmol/L, indicating deficiency. After supplementation, all studies showed reduction in mean plasma Hcy and increases in mean serum folate in all genotype groups. Pooled analysis of mean plasma Hcy levels showed that the differences between the genotype groups in both genetic models disappeared and this occurred in all subgroups including when the larger dose study was removed. Interestingly however, after supplementation, the differences in serum folate between the genotype groups became higher at 7.2 nmol/L (TT vs. CT/CC) and 8.7 nmol/L (TT vs. CC). This effect was even greater when studies that supplemented for a minimum of 8 weeks were analysed together at 8.4 nmol/L (TT vs. CT/CC) and 11.2 nmol/L (TT vs. CC). This suggested that individuals with the TT genotype did not respond as well to folic acid supplementation even if supplementation was undertaken for 8 weeks or more. Nevertheless, it is important to note that in all studies, serum folate levels were <7 nmol/L even prior to supplementation.
As our meta-analysis examined supplementation at a minimum of 400 μg per day, we were unable to examine the influence of smaller supplementation doses on response according to genotype. We acknowledge that individuals who are homozygous for the wild-type allele may respond well to a smaller dose, while individuals with two copies of the T allele may require closer to 400 μg DFE/day to obtain acceptable folate status. Notably, our pooled analysis showed that folate status was acceptable even prior to supplementation in CC and CT groups. Length of supplementation may also be an important factor. A long-term supplementation study in 144 New Zealand women of reproductive age showed that 140 μg of folic acid daily over 40 weeks was just as effective as 400 μg of folic acid daily in increasing RBC folate concentrations. As our pooled analysis focussed on supplementation studies >24 weeks, it lacked the sensitivity to detect response to smaller doses over a longer term.
None of the studies included in these meta-analyses included pregnant women. Whether there is any benefit in taking a nutrigenetic approach to folate intake in the periconceptual period and during pregnancy remains unclear. A recent study provided folic acid supplementation according to risk ranking for folate metabolism based on MTHFR C677T, A1298C and methionine synthase reductase (MTRR) A66G polymorphisms in 7,812 pregnant women in China, and reported reduced risk of pregnancy complications compared to those without supplementation [77] . However, as results were reported as case (supplementation) versus control (no supplementation), it was not possible to determine whether the effect was simply due to supplementation instead of risk ranking. Recommended intakes of for pregnancy vary in different countries from 355 to 800 μg/day DFEs [36] , with some recommendations considering genetic susceptibility to low folate status. For example, in Australia, 600 μg/day DFEs are the recommended dietary intake for pregnancy [45] ; however, the South Australian Perinatal Practice Guidelines recommend 5 mg of total folates daily for women who have a higher risk of neural tube defect birth and folate deficiency. High risk includes those with a known MTHFR mutation [78] .
There are some limitations to this meta-analysis. There were several differences between the studies, and these differences were examined by subgroup and sensitivity analyses. For example, six studies were randomised controls, and four studies were quasi-experimental trials. Nine of the studies supplemented with doses from 4 to 800 μg DFE/ day, while one supplemented with the upper tolerable limit which is 1 mg folic acid/day (1.7 mg DFE/day); three studies included males and females, and one included males only and six included females only. As males appear to have higher Hcy levels overall, sensitivity analysis was particularly important regarding this aspect [79] . Not all of the studies provided measures for plasma Hcy and serum folate for all genotypes, so analyses did not always involve the ten studies. Although red cell folate would have been a useful measure of tissue folate status, only three studies provided this data, so serum folate measures were used. Nevertheless, serum folate measures were also more appropriate to determine folate status after short-term supplementation [80] . All studies had reported that participants were not or had not recently taken folic acid supplementation, but one did not report checking for B 12 deficiency [55] . Problems inherent to the process of meta-analysis should be acknowledged, including exclusion of potentially valuable data due to missing information from studies, moderate-tohigh heterogeneity of some of the analyses, and potential publication bias.
Conclusions
In conclusion, this meta-analysis confirms that the MTHFR TT genotype is associated with increased plasma homocysteine and lowered serum folate levels and less response to short-term supplementation at levels from 400 μg per day to the upper tolerable limit. The results can be used for modelling and guiding personalised intake recommendations for the nutrient folate. More research is needed into the specialist needs of pregnancy.
